Abstract Lymphocyte activation gene 3 (LAG-3) is an inhibitory receptor that is highly
expressed by exhausted T cells. LAG-3 is a promising immunotherapeutic target, with more …

In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become
a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted …

Tumours employ various tactics to adapt and eventually resist immune attack. These
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and …

Immune-checkpoint blockade (ICB) therapies represent a paradigm shift in the treatment of
human cancers; however, it remains incompletely understood how tumor-reactive T cells …

T cell responses must be balanced to ensure adequate protection against malignant
transformation and an array of pathogens while also limiting damage to healthy cells and …

Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …

Tumor development and metastasis are facilitated by the complex interactions between
cancer cells and their microenvironment, which comprises stromal cells and extracellular …

Anti-PD-1 treatment has shown unprecedented clinical success in the treatment of non-small-
cell lung cancer (NSCLC), but the underlying mechanisms remain incompletely understood …

Single-cell RNA sequencing (scRNA-seq) has revealed an unprecedented degree of
immune cell diversity. However, consistent definition of cell subtypes and cell states across …

Lung cancer is the leading cause of cancer-related death across the world. Unlike lung
adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted …